Tolazoline

Tolazoline (Imidaline) is an α-adrenergic receptor antagonist. Tolazoline inhibits Noradrenaline (HY-13715)-induced cell contraction, modulates vascular resistance, increases arterial pressure, and reverses bradycardia and tachypnea. Tolazoline can be used to study erectile dysfunction, α₂-adrenergic receptor agonist-related poisoning, and skin vascular disease research^{[1][2][3][4][5][6][7]}. IC50 & Target:α-adrenoceptor. In Vitro:Tolazoline (1 μM; 30 s) inhibits the Noradrenaline (HY-13715)-induced contraction of isolated smooth muscle cells from human corpus cavernosum^[3].
Tolazoline inhibits the specific binding of ³H-DHE to smooth muscle cells from human corpus cavernosum with a lower affinity (IC₅₀ = 0.1 μM)^[3].
Tolazoline (10 nM-1 mM) dose-dependently reduces vascular resistance in isolated porcine perfused skin flaps precontracted with Norepinephrine (EC₅₀ = 0.288 μM)^[4].
In Vivo:Tolazoline (0.5 mg/kg; intra-arterial injection) reduces the blood flow in the coeliac artery in dogs^[6].
Tolazoline (0.5 mg/kg; iv; injected into the femoral vein) causes an increase in arterial blood pressure in cats treated with Reserpine (HY-N0480) and anesthetized with Pentobarbitone sodium^[6].
Tolazoline (2 mg/kg; i.v., once a week for 3 weeks) shortens the recumbency, head droop, reverses bradycardia and tachypnea in sheep treated with Xylazine^[7].